Alexander Constan, Ph.D.
SENIOR VICE PRESIDENT, NON CLINICAL SAFETY AND DMPK
Alex Constan has over 20 years of experience in nonclinical safety assessment and drug development. Most recently, Alex was Vice President of Nonclinical Safety at Decibel Therapeutics, where he was responsible for the safety evaluation of small molecule and gene therapy programs targeting hearing loss disorders. Prior to that, Alex was head of the Toxicology and DMPK functions at Infinity Pharmaceuticals, overseeing oncology programs from early discovery through late stage development. In addition, Alex has driven nonclinical development strategy and risk management as a toxicologist at Pfizer and Rhône-Poulenc Rorer Pharmaceuticals. Alex received a B.S. from Michigan State University, earned his Ph.D. in Environmental Toxicology at Colorado State University and trained as a post-doctoral fellow at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, NC. He also serves as a member on the Board of Health for the town of Boxford, MA.